Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director · 10% owner | June 20, 2023 | June 22, 2023 |
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | Director | February 27, 2024 | February 28, 2024 |
| Apollo Endosurgery, Inc.APEN · Entity 114713 | Director | December 29, 2016 | December 29, 2016 |
| Crinetics Pharmaceuticals, Inc.CRNX · Entity 3579 | Director | June 21, 2019 | June 25, 2019 |
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director | May 29, 2024 | May 31, 2024 |
| IO Biotech, Inc.IOBT · Entity 8764 | Director | June 08, 2023 | June 13, 2023 |
| Instil Bio, Inc.TIL · Entity 7177 | Director | June 14, 2023 | January 10, 2024 |
| REATA PHARMACEUTICALS INCRETA · Entity 12293 | Director | June 10, 2021 | June 14, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date June 20, 2023 · Filed June 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2033-06-19 | Direct | 20,200 |
Reported balance
After 2023-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 20,200 · Balance 20,200 F1: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders.
Aligos Therapeutics, Inc.
Report date February 27, 2024 · Filed February 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2031-06-17 | Direct | 0 |
Reported balance
After 2024-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2031-06-17 | Direct | 4,411 |
Reported balance
After 2024-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-28 · Grant · Acquired 4,411 · Balance 4,411 F1: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. F2: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share.
F2: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.
Apollo Endosurgery, Inc.
Report date December 29, 2016 · Filed December 29, 2016
This filing explicitly reported no securities owned.
Crinetics Pharmaceuticals, Inc.
Report date June 21, 2019 · Filed June 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.24 · Expires 2029-06-20 | Direct | 12,500 |
Reported balance
After 2019-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-21 · Grant · Acquired 12,500 · Balance 12,500 F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Harmony Biosciences Holdings, Inc.
Report date May 29, 2024 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.33 · Expires 2034-05-29 | Direct | 6,336 |
Reported balance
After 2024-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-29 · Grant · Acquired 6,336 · Balance 6,336 F1: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option shall vest in full on the earlier to occur of (i) May 29, 2025 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date.
IO Biotech, Inc.
Report date June 08, 2023 · Filed June 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.08 · Expires 2033-06-08 | Direct | 41,533 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Grant · Acquired 41,533 · Balance 41,533 F1: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.
Instil Bio, Inc.
Report date June 14, 2023 · Filed January 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.18 · Expires 2033-06-13 | Direct | 1,500 |
Reported balance
After 2023-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 1,500 · Balance 1,500 F1: The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in 12 equal monthly installments commencing on July 14, 2023, subject to the Report Person's continued service as a director through the vesting date.
REATA PHARMACEUTICALS INC
Report date June 10, 2021 · Filed June 14, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.01 · Expires 2031-06-10 | Direct | 5,000 |
Reported balance
After 2021-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 5,000 · Balance 5,000 F1: The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $146.01 · Expires 2031-06-10 | Direct | 1,201 |
Reported balance
After 2021-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-10 · Grant · Acquired 1,201 · Balance 1,201 F3: This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $100,000. F2: The options vest in the following installments: 300 shares on September 10, 2021, December 10, 2021 and March 10, 2022, respectively, and 301 shares June 10, 2022, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date.
F2: The options vest in the following installments: 300 shares on September 10, 2021, December 10, 2021 and March 10, 2022, respectively, and 301 shares June 10, 2022, subject to continued service through each vesting date.
F3: This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $100,000.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2022 Filed Apr 14, 2022 19:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,486 | $50.05 | $124,424.30 |
DisclosureSEC source: 0001104659-22-046146 · tm2211710-4_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 10,741 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 19:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,164 | $50.09 | $258,664.76 |
DisclosureSEC source: 0001104659-22-044759 · tm2211710-3_4seq1.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,093,195 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 08, 2022 Filed Apr 11, 2022 19:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 735 | $50.09 | $36,816.15 |
DisclosureSEC source: 0001104659-22-044759 · tm2211710-3_4seq1.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,227 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 19:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,610 | $50.25 | $231,652.50 |
DisclosureSEC source: 0001104659-22-044759 · tm2211710-3_4seq1.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,098,359 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 19:25 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 656 | $50.25 | $32,964.00 |
DisclosureSEC source: 0001104659-22-044759 · tm2211710-3_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 13,962 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 18:20 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 17,829 | $50.25 | $895,907.25 |
DisclosureSEC source: 0001104659-22-043316 · tm2211710-2_4seq1.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,102,969 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 18:20 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,538 | $50.25 | $127,534.50 |
DisclosureSEC source: 0001104659-22-043316 · tm2211710-2_4seq1.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,618 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 18:20 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 899 | $50.00 | $44,950.00 |
DisclosureSEC source: 0001104659-22-043316 · tm2211710-2_4seq1.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,120,798 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 18:20 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 128 | $50.00 | $6,400.00 |
DisclosureSEC source: 0001104659-22-043316 · tm2211710-2_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,156 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 18:37 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,079 | $50.00 | $103,950.00 |
DisclosureSEC source: 0001104659-22-041861 · tm2211416-1_4seq1.xml · nonDerivative · entry 6 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,121,697 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 18:37 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 296 | $50.00 | $14,800.00 |
DisclosureSEC source: 0001104659-22-041861 · tm2211416-1_4seq1.xml · nonDerivative · entry 5 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,284 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 18:37 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 6,272 | $50.15 | $314,540.80 |
DisclosureSEC source: 0001104659-22-041861 · tm2211416-1_4seq1.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,123,776 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 18:37 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 893 | $50.15 | $44,783.95 |
DisclosureSEC source: 0001104659-22-041861 · tm2211416-1_4seq1.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 17,580 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 18:37 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 24,381 | $50.24 | $1,224,901.44 |
DisclosureSEC source: 0001104659-22-041861 · tm2211416-1_4seq1.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,130,048 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 18:37 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 3,470 | $50.24 | $174,332.80 |
DisclosureSEC source: 0001104659-22-041861 · tm2211416-1_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 18,473 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 29, 2022 Filed Mar 29, 2022 20:40 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 30,996 | $50.89 | $1,577,386.44 |
DisclosureSEC source: 0001104659-22-039635 · tm228148-9_4seq1.xml · nonDerivative · entry 6 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,154,429 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.03 to $52.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 29, 2022 Filed Mar 29, 2022 20:40 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,412 | $50.89 | $224,526.68 |
DisclosureSEC source: 0001104659-22-039635 · tm228148-9_4seq1.xml · nonDerivative · entry 5 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 21,943 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.03 to $52.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 20:40 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 37,195 | $50.82 | $1,890,249.90 |
DisclosureSEC source: 0001104659-22-039635 · tm228148-9_4seq1.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,185,425 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 20:40 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,294 | $50.82 | $269,041.08 |
DisclosureSEC source: 0001104659-22-039635 · tm228148-9_4seq1.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 26,355 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:40 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 31,710 | $50.24 | $1,593,110.40 |
DisclosureSEC source: 0001104659-22-039635 · tm228148-9_4seq1.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,222,620 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.48 to $51.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 20:40 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 4,514 | $50.24 | $226,783.36 |
DisclosureSEC source: 0001104659-22-039635 · tm228148-9_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,649 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.48 to $51.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 24, 2022 Filed Mar 24, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 16,576 | $50.12 | $830,789.12 |
DisclosureSEC source: 0001104659-22-037649 · tm228148-7_4seq1.xml · nonDerivative · entry 6 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,254,330 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 24, 2022 Filed Mar 24, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 2,359 | $50.12 | $118,233.08 |
DisclosureSEC source: 0001104659-22-037649 · tm228148-7_4seq1.xml · nonDerivative · entry 5 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 36,163 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F6 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 9,439 | $50.25 | $474,309.75 |
DisclosureSEC source: 0001104659-22-037649 · tm228148-7_4seq1.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,270,906 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,344 | $50.25 | $67,536.00 |
DisclosureSEC source: 0001104659-22-037649 · tm228148-7_4seq1.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 38,522 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $51.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,757 | $50.13 | $288,598.41 |
DisclosureSEC source: 0001104659-22-037649 · tm228148-7_4seq1.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,280,345 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 22, 2022 Filed Mar 24, 2022 20:07 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 819 | $50.13 | $41,056.47 |
DisclosureSEC source: 0001104659-22-037649 · tm228148-7_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 39,866 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 9,003 | $50.10 | $451,050.30 |
DisclosureSEC source: 0001104659-22-036243 · tm228148-6_4seq1.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,286,097 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 18, 2022 Filed Mar 21, 2022 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,282 | $50.10 | $64,228.20 |
DisclosureSEC source: 0001104659-22-036243 · tm228148-6_4seq1.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 40,685 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F5 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 5,161 | $50.05 | $258,308.05 |
DisclosureSEC source: 0001104659-22-036243 · tm228148-6_4seq1.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,295,100 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F2 · ownership.nature: The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 20:31 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 735 | $50.05 | $36,786.75 |
DisclosureSEC source: 0001104659-22-036243 · tm228148-6_4seq1.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 41,967 F3 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021. F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $50.00 to $50.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionSeries C Preferred Stock · Derivative | 188,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-037652 · form4.xml · derivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,365,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | PurchaseCommon Stock | 650,000 | $14.00 | $9,100,000.00 |
DisclosureSEC source: 0001140361-21-037652 · form4.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,015,545 F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 09, 2021 Filed Nov 12, 2021 21:15 UTC | IO Biotech, Inc. IOBT · Entity 8764 | ConversionCommon Stock | 2,365,545 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-037652 · form4.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,365,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of Series C Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into the number of shares of Common Stock reported in Column 7 of Table II. These shares of Series C Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The reporting person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 22:46 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001567619-21-012370 · doc1.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 22:59 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 12,004 | $0.00 Strike: $59.66 | $0.00 |
DisclosureSEC source: 0001209191-21-040732 · doc4.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,004 Underlying: Common Stock · 12,004 shares Expires 2031-06-10 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:26 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantStock Option (right to buy) · Derivative | 1,201 | $83.24 Strike: $146.01 | $99,971.24 |
DisclosureSEC source: 0001209191-21-040136 · doc4.xml · derivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,201 Underlying: Class A common stock · 1,201 shares Expires 2031-06-10 F3 · price: This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $100,000. F2 · derivative.exercise_date: The options vest in the following installments: 300 shares on September 10, 2021, December 10, 2021 and March 10, 2022, respectively, and 301 shares June 10, 2022, subject to continued service through each vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 11:26 UTC | REATA PHARMACEUTICALS INC RETA · Entity 12293 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $146.01 | $0.00 |
DisclosureSEC source: 0001209191-21-040136 · doc4.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A common stock · 5,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The options vest in 4 equal installments on September 10, 2021, December 10, 2021, March 10, 2022, and June 10, 2022, subject to continued service through each vesting date. Read SEC document |
| May 20, 2021 Filed Jun 14, 2021 16:30 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 7,246 | $0.00 Strike: $32.50 | $0.00 |
DisclosureSEC source: 0000899243-21-023566 · doc4.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,246 Underlying: Common Stock · 7,246 shares Expires 2031-05-20 F1 · derivative.exercise_date: The stock option shall vest in full on the earlier to occur of (i) May 20, 2022 and (ii) the date of the next annual meeting following the grant date, subject to continued service through the applicable vesting date. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 17:30 UTC | Instil Bio, Inc. TIL · Entity 7177 | ConversionSeries C Preferred Stock · Derivative | 397,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023064 · doc4.xml · derivative · entry 5 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 477,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The Reporting Person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 17:30 UTC | Instil Bio, Inc. TIL · Entity 7177 | ConversionSeries B Preferred Stock · Derivative | 9,758,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023064 · doc4.xml · derivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 11,709,696 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The Reporting Person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 17:30 UTC | Instil Bio, Inc. TIL · Entity 7177 | PurchaseCommon Stock | 300,000 | $20.00 | $6,000,000.00 |
DisclosureSEC source: 0001209191-21-023064 · doc4.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,486,787 F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The Reporting Person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 17:30 UTC | Instil Bio, Inc. TIL · Entity 7177 | ConversionCommon Stock | 477,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-023064 · doc4.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,186,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The Reporting Person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 17:30 UTC | Instil Bio, Inc. TIL · Entity 7177 | ConversionCommon Stock | 11,709,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-023064 · doc4.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,709,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date. F2 · ownership.nature: The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. The Reporting Person is a managing member of Capital IX and may be deemed to share voting and investment power with respect to the shares beneficially owned by Fund IX and disclaims Section 16 beneficial ownership of such securities held by Fund IX, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:56 UTC | Instil Bio, Inc. TIL · Entity 7177 | GrantStock Option (right to buy) · Derivative | 52,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-022477 · doc4.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 52,000 shares Expires 2031-03-18 F1 · derivative.exercise_date: The option will vest in 36 equal monthly installments commencing on April 18, 2021, subject to the Report Person's continued service as a director through the vesting date. Read SEC document |
| August 26, 2020 Filed Aug 27, 2020 19:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | PurchaseCommon Stock | 3,922 | $34.30 | $134,524.60 |
DisclosureSEC source: 0000899243-20-023547 · doc4.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 42,702 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $33.9 to $35.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 19:26 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | PurchaseCommon Stock | 823 | $34.20 | $28,146.60 |
DisclosureSEC source: 0000899243-20-023547 · doc4.xml · nonDerivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 38,780 F2 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $33.3 to $34.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (2) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| August 24, 2020 Filed Aug 24, 2020 21:09 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | PurchaseCommon Stock | 3,057 | $34.30 | $104,855.10 |
DisclosureSEC source: 0000899243-20-023341 · doc4.xml · nonDerivative · entry 4 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 37,957 F4 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $35.0 to $33.8, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 21:09 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | PurchaseCommon Stock | 7,352 | $34.10 | $250,703.20 |
DisclosureSEC source: 0000899243-20-023341 · doc4.xml · nonDerivative · entry 3 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 34,900 F3 · price: The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $33.3 to $35.0, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| August 21, 2020 Filed Aug 24, 2020 21:09 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | PurchaseCommon Stock | 24,812 | $24.00 | $595,488.00 |
DisclosureSEC source: 0000899243-20-023341 · doc4.xml · nonDerivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,548 F2 · price: The price reported herein is the public offering price. F1 · ownership.nature: The shares are held of record by Vivo Capital Fund IX, L.P. Vivo Capital IX, LLC is the General Partner of Vivo Capital Fund IX, L.P. As a managing member of Vivo Capital IX, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund IX, L.P with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.